InVivo Therapeutics is focused on developing and commercializing groundbreaking treatments for spinal cord injuries (SCI).
We intend to leverage our platform technology to deliver several products to the market including:
A biocompatible Neuro-Spinal Scaffold
to treat acute SCI
A biocompatible Neuro-Spinal Scaffold Plus Stem Cells to treat chronic SCI
InVivo’s proprietary technology was co-invented by Robert S. Langer, ScD, the David H. Koch Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, MD, affiliated with Massachusetts General Hospital. The patent rights that are the basis for InVivo’s products are under an exclusive, worldwide license from Children’s Medical Center Corporation and Massachusetts Institute of Technology.
Data on InVivo’s technology was first published in PNAS in 2002 and has since been demonstrated to successfully promote functional recovery following traumatic spinal cord injury in several models including rodent and non-human primate models. Data from InVivo’s pilot non-human primate study was published in the Journal of Neuroscience Methods in 2010.